Companies · Biotechnology

Achieve Life Sciences, Inc.

Vancouver, B.C. · Biotechnology

Diligence memoA one-page analyst read on Achieve Life Sciences, Inc. — recommendation, valuation, rhythm, risks.
$28.9M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 27%
Sector rank · raised
Series B
Latest stage · inferred · Fri Nov 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Achieve Life Sciences, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.61× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.6 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Achieve Life Sciences, Inc. is one of 4291 Biotechnology companies tracked from Vancouver, B.C.. By capital raised it ranks in the upper tier (ahead of 74% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
16
Investors (latest)
2022-11-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2009-12-24 Raised $10M (real) Modeled valuation $362M (est)$10M$362MSeries A2009Series B · 2022-11-18 Raised $19M (real) Modeled valuation $270M (est)$19M$270MSeries B2022Series B · 2022-11-18 Raised $19M (real) Modeled valuation $270M (est)$19M$270MSeries B2022+$19M+$19MCumulative $48M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.0M · 2009
Series B$18.9M · 2022
Series B extension$18.9M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$269.7M
Base estimate est.
$37.8M
Conservative case
$657.8M
Upside case
$105.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $361.5M · 2009-12-242009Series B · modeled $269.7M · 2022-11-18Series B · modeled $269.7M · 2022-11-182022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
3.6 yr
Elapsed time used
3.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
77 mo
Avg between rounds
$2.2M/yr
Capital velocity
16.5 yr
On record since
2009
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.0× above median
This company$28.9M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.1× above median
This company$18.9M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 4.2× above median
This company$269.7M
Sector median$64.2M

Raised more than 74% of sector peers (real $). Modeled value above 75% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #51 of 197.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $737.5M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $617.6M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.1M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $590.7M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $569.5M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $553.9M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.2M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.0M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.0M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $491.7M (est)Achieve Life Sciences, Inc. (this company) Raised $28.9M · modeled $269.7M (est)Achieve Life Sciences, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$737.5M4.41×
YAP Therapeutics IncSeries B$30.1M$617.6M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.1M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$590.7M3.53×
EpiBiologics, Inc.Series B$30.0M$569.5M3.40×
GIOGI LtdSeries B$27.3M$553.9M3.31×
SonoThera, Inc.Series B$30.4M$550.2M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.0M3.25×
GIOHEALTH LtdSeries B$24.5M$498.0M2.97×
GIOCAN LtdSeries B$24.5M$498.0M2.97×
GIODIA LtdSeries B$24.5M$498.0M2.97×
Cerapedics IncSeries B$99.1M$491.7M2.94×
Achieve Life Sciences, Inc. this companySeries B$28.9M$269.7M1.61×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.0M2009-12-24$45.5M$361.5M85%
Series B$18.9M2022-11-18$105.0M$269.7M90%
Series B$18.9M2022-11-18$105.0M$269.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.0M2009-12-24
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series B$18.9M2022-11-18
    • Raised again after 155 mo — slower than the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 16 investors on this round.
  3. Series B$18.9M2022-11-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 16 investors on this round.
Intelligence
2029 ~Q2
Modeled next raise · ~77mo cadence
$18.9M
Modeled next size est.range $18.9M$30.2M
1.0×
Last step-up
$2.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Bencich2 other2022-11
Anthony Clarke1 other2022-11
Cindy Jacobs1 other2022-11
Donald Joseph1 other2022-11
Jay Moyes1 other2022-11
Michael A. Martino1 other2009-12
Bridget Martell2022-11
Cindy A. Jacobs2009-12
Dwight A. Winstead2009-12
Jaime Xinos2022-11
Martin Mattingly2022-11
Michelle A. Burris2009-12
Neil James Clendeninn2009-12
Richard Stewart2022-11
Scott Cormack2009-12
Stephen A. Anderson2009-12
Vaughn Himes2022-11
Registry & provenance

Achieve Life Sciences, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
949858
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Integrated Diagnostics, Inc.BiotechnologySeries B$45.3M$242.1Mnetwork2 shared operators · same sector · same stage
Cadence Neuroscience, Inc.BiotechnologySeries B$29.0M$332.2Msame sector · same stage
Spyryx Biosciences, Inc.BiotechnologySeries B$29.1M$235.4Msame sector · same stage
Rebiotix Inc.BiotechnologySeries B$29.3M$338.0Msame sector · same stage
Basking Biosciences, Inc.BiotechnologySeries B$29.4M$261.0Msame sector · same stage
Andes AG, Inc.BiotechnologySeries B$28.1M$193.3Msame sector · same stage
Neuraptive Therapeutics, Inc.BiotechnologySeries B$29.8M$295.0Msame sector · same stage
Brenig Therapeutics, Inc.BiotechnologySeries B$30.0M$210.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Overture Life, Inc.BiotechnologySeries A$491.7M90%
Leading Biosciences, Inc.BiotechnologySeries B$557.6M88%
SELLAS Life Sciences Group, Inc.BiotechnologySeries B$148.6M88%
Inspired Life Medical, Inc.BiotechnologySeed$127.4M87%
Love Lifesciences LLCBiotechnologyPre-Seed$3.5M87%
Biolife Solutions IncBiotechnologySeries A$76.3M87%
ENDRA Life Sciences Inc.BiotechnologySeries A$40.8M87%
Origin Life Sciences, Inc.BiotechnologySeed$5.8M87%
Frequently asked
How much funding has Achieve Life Sciences, Inc. raised?
Achieve Life Sciences, Inc. has raised approximately $28.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Achieve Life Sciences, Inc.'s estimated valuation?
Provath's modeled valuation for Achieve Life Sciences, Inc. is approximately $269.7M (modeled range $37.8M–$657.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Achieve Life Sciences, Inc. at?
Achieve Life Sciences, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Nov 18.
What does Achieve Life Sciences, Inc. do and where is it based?
Achieve Life Sciences, Inc. operates in the Biotechnology sector, based in Vancouver, B.C..
Explore related

See where Achieve Life Sciences, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Achieve Life Sciences, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.